Literature DB >> 18164543

N-(4-Hydroxyphenyl)retinamide induced differentiation with repression of telomerase and cell cycle to increase interferon-gamma sensitivity for apoptosis in human glioblastoma cells.

Rajiv Janardhanan1, Naren L Banik, Swapan K Ray.   

Abstract

Glioblastoma is the most malignant and prevalent brain tumor in humans. It is composed of heterogenic abnormal astroglial cells that avoid differentiation, maintain proliferation, and hardly commit apoptosis. N-(4-Hydroxyphenyl)retinamide (4-HPR) induced astrocytic differentiation and increased sensitivity to interferon-gamma (IFN-gamma) for apoptosis in human glioblastoma A172, LN18, and SNB19 cells. Combination of 4-HPR and IFN-gamma significantly inhibited human telomerase reverse transcriptase (hTERT), cyclin dependent kinase 2 (CDK2), and survivin to up-regulate caspase-8, caspase-9, and caspase-3 for increasing apoptosis in all glioblastoma cell lines. Hence, combination of 4-HPR and IFN-gamma should be considered for controlling growth of different human glioblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18164543      PMCID: PMC3103940          DOI: 10.1016/j.canlet.2007.11.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  46 in total

1.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.

Authors:  G Ambrosini; C Adida; D C Altieri
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

2.  Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization.

Authors:  S M Srinivasula; M Ahmad; T Fernandes-Alnemri; E S Alnemri
Journal:  Mol Cell       Date:  1998-06       Impact factor: 17.970

3.  Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.

Authors:  A L Sabichi; D T Hendricks; M A Bober; M J Birrer
Journal:  J Natl Cancer Inst       Date:  1998-04-15       Impact factor: 13.506

4.  Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat.

Authors:  F Burke; N East; C Upton; K Patel; F R Balkwill
Journal:  Eur J Cancer       Date:  1997-06       Impact factor: 9.162

5.  Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme.

Authors:  Y Hayashi; K Ueki; A Waha; O D Wiestler; D N Louis; A von Deimling
Journal:  Brain Pathol       Date:  1997-07       Impact factor: 6.508

6.  Reduction of both RAR and RXR levels is required to maximally alter sensitivity of CA-OV3 ovarian tumor cells to growth suppression by all-trans-retinoic acid.

Authors:  S Wu; Z P Zhang; D Zhang; D R Soprano; K J Soprano
Journal:  Exp Cell Res       Date:  1997-11-25       Impact factor: 3.905

Review 7.  A decade of molecular biology of retinoic acid receptors.

Authors:  P Chambon
Journal:  FASEB J       Date:  1996-07       Impact factor: 5.191

8.  Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.

Authors:  M E Hegi; A zur Hausen; D Rüedi; G Malin; P Kleihues
Journal:  Int J Cancer       Date:  1997-09-26       Impact factor: 7.396

9.  Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.

Authors:  G P Kalemkerian; R Slusher; S Ramalingam; S Gadgeel; M Mabry
Journal:  J Natl Cancer Inst       Date:  1995-11-15       Impact factor: 13.506

Review 10.  The epidemiology of prostate cancer: clues for chemoprevention.

Authors:  K J Pienta
Journal:  In Vivo       Date:  1994 May-Jun       Impact factor: 2.155

View more
  8 in total

1.  Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines.

Authors:  Joseph George; Naren L Banik; Swapan K Ray
Journal:  Int J Biochem Cell Biol       Date:  2010-04-13       Impact factor: 5.085

2.  High levels of β-catenin promote IFNγ-induced apoptosis in hepatocellular carcinoma cells.

Authors:  Wei Li; Hongfei Tong; Xiaojie Huang; Wen Wang; Hao Wu; Shengzhang Lin
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

3.  Priming effect of aspirin for tumor cells to augment cytotoxic action of cisplatin against tumor cells: implication of altered constitution of tumor microenvironment, expression of cell cycle, apoptosis, and survival regulatory molecules.

Authors:  Anjani Kumar; Sukh Mahendra Singh
Journal:  Mol Cell Biochem       Date:  2012-08-15       Impact factor: 3.396

4.  Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.

Authors:  Mrinmay Chakrabarti; Mehrab Khandkar; Naren L Banik; Swapan K Ray
Journal:  Brain Res       Date:  2012-03-13       Impact factor: 3.252

5.  N-(4-Hydroxyphenyl) retinamide potentiated paclitaxel for cell cycle arrest and apoptosis in glioblastoma C6 and RG2 cells.

Authors:  Rajiv Janardhanan; Jonathan T Butler; Naren L Banik; Swapan K Ray
Journal:  Brain Res       Date:  2009-03-10       Impact factor: 3.252

6.  N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53.

Authors:  Rajiv Janardhanan; Naren L Banik; Swapan K Ray
Journal:  Biochem Pharmacol       Date:  2009-06-18       Impact factor: 5.858

7.  Downregulation of A20 increases the cytotoxicity of IFN-γ in hepatocellular carcinoma cells.

Authors:  Lei Yin; Zheng Fang; Ning-Jia Shen; Ying-He Qiu; Ai-Jun Li; Yong-Jie Zhang
Journal:  Drug Des Devel Ther       Date:  2017-09-26       Impact factor: 4.162

8.  Bryostatin-1, Fenretinide and 1α,25 (OH)(2)D(3) Induce Growth Inhibition, Apoptosis and Differentiation in T and B Cell-Derived Acute Lymphoblastic Leukemia Cell Lines (CCRF-CEM and Nalm-6).

Authors:  Ali M Ardekani; Shahrzad Soleymani Fard; Mahmood Jeddi-Tehrani; Ramin Ghahremanzade
Journal:  Avicenna J Med Biotechnol       Date:  2011-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.